Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation

BMC Biotechnology

Volumn 10, Issue , 2010, Pages

  Kirschning, Carsten J ^a   Dreher, Stefan ^b   Maaß, Björn ^c   Fichte, Sylvia ^b   Schade, Jutta ^c   Köster, Mario ^c   Noack, Andreas ^c   Lindenmaier, Werner ^c   Wagner, Hermann ^b   Böldicke, Thomas ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; CELL ACTIVATION; CELL SURFACE MOLECULES; CELL SURFACES; CHRONIC INFLAMMATION; CO-EXPRESSION; CO-IMMUNOPRECIPITATIONS; CO-TRANSFECTIONS; COEXPRESSED; COGNATE ANTIGENS; EX-VIVO; HEAVY CHAIN; HEK293 CELLS; HIGH EFFICIENCY; IMMUNE CELLS; IMMUNE RESPONSE; IN-VITRO; INNATE IMMUNE SYSTEMS; LIGHT CHAIN; MONOCLONAL ANTIBODIES (MAB); OPEN READING FRAME; PATHOGEN-ASSOCIATED MOLECULAR PATTERNS; PATTERN RECOGNITION RECEPTORS; PLASMID ENCODING; RECOMBINANT ADENOVIRUS; REPORTER GENE; SPLENOCYTES; SURFACE EXPRESSION; TARGET PROTEINS; THERAPEUTIC POTENTIALS; TOLL-LIKE RECEPTORS; VARIABLE DOMAIN; VIRAL INFECTIONS;

AMINO ACIDS; BACTERIOPHAGES; CELL MEMBRANES; ENZYME ACTIVITY; MACROPHAGES; MONOCLONAL ANTIBODIES; NUCLEIC ACIDS; ORGANIC ACIDS; PATHOLOGY; PATTERN RECOGNITION;

CYTOLOGY;

ADENOVIRUS VECTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MESSENGER RNA; MONOCLONAL ANTIBODY T2.5; PEPTIDE DERIVATIVE; RECOMBINANT ANTIBODY; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 ANTIBODY; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRIPALMITOYL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; BONE MARROW; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE RELEASE; EMBRYO; ENDOPLASMIC RETICULUM; EX VIVO STUDY; GENE ACTIVATION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPRECIPITATION; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION INHIBITION; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; PROTEIN EXPRESSION; PROVOCATION TEST; REPORTER GENE; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPLEEN CELL; ADENOVIRUS; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; GENE VECTOR; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADENOVIRIDAE; MURINAE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; CELL LINE; ENDOPLASMIC RETICULUM; GENETIC VECTORS; HUMANS; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; TOLL-LIKE RECEPTOR 2; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950662686     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-10-31     Document Type: Article

References (46)

1. Medzhitov R, Janeway CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-8. 10.1016/S0092-8674(00)80412-2, 9363937.
2. Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 2006, 66:15-29. 10.2165/00003495-200666010-00002, 16398566.
3. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005, 365:63-78. 10.1016/S0140-6736(04)17667-8, 15639681.
4. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol Rev 2004, 202:250-65. 10.1111/j.0105-2896.2004.00202.x, 15546398.
5. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998, 95:13875-80. 10.1073/pnas.95.23.13875, 24941, 9811894.
6. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S, Wagner H, Kirschning CJ. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004, 113:1473-81. 406529, 15146245.
7. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-9. 10.1038/nm1589, 17479101.
8. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999, 18:551-7. 10.1038/sj.onc.1202338, 9927212.
9. Tse E, Rabbitts TH. Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. Proc Natl Acad Sci USA 2000, 97:12266-71. 10.1073/pnas.97.22.12266, 17330, 11050246.
10. Wheeler YY, Chen SY, Sane DC. Intrabody and intrakine strategies for molecular therapy. Mol Ther 2003, 8:355-66. 10.1016/S1525-0016(03)00183-7, 12946308.
11. Cao T, Heng BC. Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Ann Clin Lab Sci 2005, 35:227-9.
12. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005, 11:263-70. 10.1038/nm1191, 15723075.
13. Boldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 2007, 11:54-70. 10.1111/j.1582-4934.2007.00002.x, 17367501.
14. Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem 2003, 278:47812-9. 10.1074/jbc.M307002200, 12947084.
15. Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 2005, 65:972-81.
16. Poznansky MC, Foxall R, Mhashilkar A, Coker R, Jones S, Ramstedt U, Marasco W. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther 1998, 9:487-96. 10.1089/hum.1998.9.4-487, 9525310.
17. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, Torbett BE. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 2006, 13:1480-92. 10.1038/sj.gt.3302801, 16738691.
18. Richardson JH, Sodroski JG, Waldmann TA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the a subunit of the receptor. Proc Natl Acad Sci 1995, 92:3137-3141. 10.1073/pnas.92.8.3137, 42120, 7724529.
19. Busch A, Marasco WA, Doebis C, Volk HD, Seifert M. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies-a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods 2004, 34:240-249. 10.1016/j.ymeth.2004.03.017, 15312677.
20. Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol 2008, 8:1-13. 10.1186/1472-6750-8-5, 2254392, 18184429.
21. Strebe N, Guse A, Schüngel M, Schirrmann T, Hafner M, Jostock T, Hust M, Müller W, Dübel S. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. J Immunol Methods 2009, 341:30-40. 10.1016/j.jim.2008.10.012, 19038261.
22. Lewis MJ, Pelham HRB. Ligand-induced redistribution of a human KDEL receptor from the Golgi complex to the endoplasmic reticulum. Cell 1992, 68:353-64. 10.1016/0092-8674(92)90476-S, 1310258.
23. Donoso G, Herzog V, Schmitz A. Misfolded BiP is degraded by a proteasome-independent endoplasmic-reticulum-associated degradation pathway. Biochem J 2005, 387:897-903. 10.1042/BJ20041312, 1135023, 15610068.
24. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 2005, 7:766-72. 10.1038/ncb0805-766, 16056268.
25. Schmitz A, Schneider A, Kummer MP, Herzog V. Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic 2004, 5:89-101. 10.1111/j.1600-0854.2004.00159.x, 14690498.
26. van Anken E, Braakman I. Versatility of the endoplasmic reticulum protein folding factory. Crit Rev Biochem Mol Biol 2005, 40:191-228. 10.1080/10409230591008161, 16126486.
27. Uematsu S, Akira S. The role of Toll-like receptors in immune disorders. Expert Opin Biol Ther 2006, 6:203-14. 10.1517/14712598.6.3.203, 16503731.
28. Kaner RJ, Worgall S, Leopold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J, Finberg R, Falck-Pedersen E, Crystal RG. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. Am J Respir Cell Mol Biol 1999, 20:361-370.
29. Loo FAJ, de Hooge ASK, Smeets RL, Bakker AC, Bennink MB, Arntz OJ, Joosten LAB, van Beuningen HM, Kraan PK, Varley AW, Berg WB. An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther 2004, 11:581-590. 10.1038/sj.gt.3302182, 14973543.
30. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B. Toll-like Receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Am Soc Gene Ther 2007, 15:378-385.
31. Haisma HJ, Boesjes M, Beerens AM, Strate BWA, Curiel DT, Plüddemann A, Gordon S, Bellu AR. Scavenger Receptor A: A new route for adenovirus 5. Mol Pharm 2009, 6:366-374. 10.1021/mp8000974, 19227971.
32. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2003, 5:451-462. 10.1002/jgm.409, 12797110.
33. Brantl S. Antisense-RNA regulation and RNA interference. Biochim Biophys Acta 2002, 1575:15-25.
34. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4:346-58. 10.1038/nrg1066, 12728277.
35. Lavillette D, Russell SJ, Cosset FL. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol 2001, 12:461-6. 10.1016/S0958-1669(00)00246-9, 11604321.
36. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004, 4:1-14. 10.2174/1566523044577997, 15032610.
37. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay S, Lauener RP. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003, 162:1221-7. 1851232, 12651614.
38. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106. 10.1038/nature07623, 2746432, 19122641.
39. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strobe W. Current Protocols in Immunology. 1990, NY: John Wiley & Sons, Inc.
40. Spiller S, Dreher S, Meng G, Grabiec A, Thomas W, Hartung T, Pfeffer K, Hochrein H, Brade H, Bessler W, Wagner H, Kirschning CJ. Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4. J Biol Chem 2007, 282:13190-8. 10.1074/jbc.M610340200, 17353199.
41. Pope AR, Embleton MJ, Mernaugh R. Construction and use of antibody gene repertoires. Antibody Engineering 1996, 1-40. Oxford University Press, Oxford, New York, Tokyo, McCafferty J, Hoogenboom HR, Chiswell DJ.
42. Böldicke T, Tesar M, Griesel C, Rohde M, Gröne HJ, Waltenberger J, Kollet O, Lapidot T, Yayon A, Weich H. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem cells 2001, 19:24-36. 10.1634/stemcells.19-1-24, 11209088.
43. Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem 2005, 95:827-39. 10.1002/jcb.20462, 15838884.
44. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995, 3:207-20.
45. Boldicke T, Weber H, Mueller PP, Barleon B, Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J Immunol Methods 2005, 300:146-59. 10.1016/j.jim.2005.03.007, 15946674.
46. Meng G, Grabiec A, Vallon M, Ebe B, Hampel S, Bessler W, Wagner H, Kirschning CJ. Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucin-rich repaet (LRR)/LRR-like motifs of TLR2. J Biol Chem 2003, 278:39822-39829. 10.1074/jbc.M304766200, 12860988.